

Claims 1-28 (canceled).

Claims 29 (withdrawn) A method of treating a condition mediated by DPP-IV or PPAP α , comprising administering to a warm-blooded animal in need thereof jointly therapeutically effective amounts of a DPP-IV-inhibitor (S)-1-[(3-hydroxy-1-adamantyl)amino]acetyl-2-cyano-pyrrolidine (LAF237) in free or pharmaceutically acceptable salt form and at least one PPAR α compound, or the pharmaceutically acceptable salts of such compounds.

Claim 30 (withdrawn) The method of claim 29, wherein the condition is dyslipidemia or obesity.

Claim 31 (withdrawn) The method according to claim 29, wherein the condition mediated by DPP-IV or PPAR α is selected from diabetes, type 2 diabetes mellitus, conditions of IGT, conditions of impaired fasting plasma glucose, metabolic acidosis, ketosis, arthritis, obesity, dyslipidemia and osteoporosis.

Claim 32 (new) A combination comprising (S)-1-[(3-hydroxy-1-adamantyl)amino]acetyl-2-cyano-pyrrolidine (LAF237) in free form or in an acid addition salt form and at least one peroxisome proliferators-activated receptor α (PPAR α) compound in free form or in an acid addition salt form.

Claim 33 (new) The combination of claim 32, wherein the PPAR α compound is selected from the group consisting of fenofibrate, micronized fenofibrate, bezafibrate, gemfibrozil and ciprofibrate or the pharmaceutically acceptable salt thereof.

Claim 34 (new) The combination of claim 32, wherein the PPAR α compound is micronized fenofibrate.